278 related articles for article (PubMed ID: 12937968)
1. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.
Kayser O; Olbrich C; Croft SL; Kiderlen AF
Parasitol Res; 2003 Jun; 90 Suppl 2():S63-70. PubMed ID: 12937968
[TBL] [Abstract][Full Text] [Related]
2. Delivery strategies for antiparasitics.
Kayser O; Kiderlen AF
Expert Opin Investig Drugs; 2003 Feb; 12(2):197-207. PubMed ID: 12556214
[TBL] [Abstract][Full Text] [Related]
3. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles.
Date AA; Joshi MD; Patravale VB
Adv Drug Deliv Rev; 2007 Jul; 59(6):505-21. PubMed ID: 17574295
[TBL] [Abstract][Full Text] [Related]
4. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs.
Chen J; Lu WL; Gu W; Lu SS; Chen ZP; Cai BC; Yang XX
Expert Opin Drug Deliv; 2014 Apr; 11(4):565-77. PubMed ID: 24490763
[TBL] [Abstract][Full Text] [Related]
5. Nanomaterials as a Potential Target for Infectious Parasitic Agents.
Alsharedeh RH; Rezigue M; Bashatwah RM; Amawi H; Aljabali AAA; Obeid MA; Tambuwala MM
Curr Drug Deliv; 2024; 21(6):828-851. PubMed ID: 36815647
[TBL] [Abstract][Full Text] [Related]
6. Natural products as antiparasitic drugs.
Kayser O; Kiderlen AF; Croft SL
Parasitol Res; 2003 Jun; 90 Suppl 2():S55-62. PubMed ID: 12937967
[TBL] [Abstract][Full Text] [Related]
7. [Antiparasitic drugs. Review of the useful drugs in the treatment of classic and emergent parasitic diseases].
Pérez JL; Carranza C; Mateos F
Rev Esp Quimioter; 2009 Jun; 22(2):93-105. PubMed ID: 19544101
[TBL] [Abstract][Full Text] [Related]
8. Cyclodextrin based nanosponges for pharmaceutical use: a review.
Tejashri G; Amrita B; Darshana J
Acta Pharm; 2013 Sep; 63(3):335-58. PubMed ID: 24152895
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles for antiparasitic drug delivery.
Sun Y; Chen D; Pan Y; Qu W; Hao H; Wang X; Liu Z; Xie S
Drug Deliv; 2019 Dec; 26(1):1206-1221. PubMed ID: 31746243
[TBL] [Abstract][Full Text] [Related]
10. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues.
González-Díaz H; Romaris F; Duardo-Sanchez A; Pérez-Montoto LG; Prado-Prado F; Patlewicz G; Ubeira FM
Curr Pharm Des; 2010; 16(24):2737-64. PubMed ID: 20642428
[TBL] [Abstract][Full Text] [Related]
11. Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation.
Mennini N; Cirri M; Maestrelli F; Mura P
Int J Pharm; 2016 Dec; 515(1-2):684-691. PubMed ID: 27825863
[TBL] [Abstract][Full Text] [Related]
12. Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer.
Priotti J; Baglioni MV; García A; Rico MJ; Leonardi D; Lamas MC; Menacho Márquez M
AAPS PharmSciTech; 2018 Nov; 19(8):3734-3741. PubMed ID: 30255471
[TBL] [Abstract][Full Text] [Related]
13. Cyclodextrins in drug delivery.
Loftsson T; Jarho P; Másson M; Järvinen T
Expert Opin Drug Deliv; 2005 Mar; 2(2):335-51. PubMed ID: 16296758
[TBL] [Abstract][Full Text] [Related]
14. Supramolecular approaches for drug development.
Kawakami K; Ebara M; Izawa H; Sanchez-Ballester NM; Hill JP; Ariga K
Curr Med Chem; 2012; 19(15):2388-98. PubMed ID: 22455591
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Inhibitors as Antiparasitic Drugs: Pharmacological, Biochemical and Molecular Perspectives.
Mukherjee S; Mukherjee N; Gayen P; Roy P; Babu SP
Curr Drug Metab; 2016; 17(10):937-970. PubMed ID: 27719626
[TBL] [Abstract][Full Text] [Related]
16. Development of a new delivery system consisting in "drug--in cyclodextrin--in nanostructured lipid carriers" for ketoprofen topical delivery.
Cirri M; Bragagni M; Mennini N; Mura P
Eur J Pharm Biopharm; 2012 Jan; 80(1):46-53. PubMed ID: 21839833
[TBL] [Abstract][Full Text] [Related]
17. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
18. From chemical graphs in computer-aided drug design to general Markov-Galvez indices of drug-target, proteome, drug-parasitic disease, technological, and social-legal networks.
Riera-Fernández P; Munteanu CR; Dorado J; Martin-Romalde R; Duardo-Sanchez A; González-Diaz H
Curr Comput Aided Drug Des; 2011 Dec; 7(4):315-37. PubMed ID: 22050683
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical characterization by AFM, FT-IR and DSC and biological assays of a promising antileishmania delivery system loaded with a natural Brazilian product.
Marquele-Oliveira F; Torres EC; Barud Hda S; Zoccal KF; Faccioli LH; Hori JI; Berretta AA
J Pharm Biomed Anal; 2016 May; 123():195-204. PubMed ID: 26897464
[TBL] [Abstract][Full Text] [Related]
20. Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.
Borsari C; Santarem N; Torrado J; Olías AI; Corral MJ; Baptista C; Gul S; Wolf M; Kuzikov M; Ellinger B; Witt G; Gribbon P; Reinshagen J; Linciano P; Tait A; Costantino L; Freitas-Junior LH; Moraes CB; Bruno Dos Santos P; Alcântara LM; Franco CH; Bertolacini CD; Fontana V; Tejera Nevado P; Clos J; Alunda JM; Cordeiro-da-Silva A; Ferrari S; Costi MP
Eur J Med Chem; 2017 Jan; 126():1129-1135. PubMed ID: 28064141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
